Malla Curricular De La Carrera De Ingeniería En Mantenimiento Automotriz De La Universidad Técnica Del Norte

Esta investigación se desarrolla en el sector norte del país (Otavalo, Atuntaqui, Ibarra, San Gabriel, Tulcán) en los Talleres, Mecánicas, Empresas y en la Universidad Técnica del Norte en donde se puede obtener información acerca de las necesidades que tiene el sector automotriz del norte del país. En este contexto se generó la investigación que permitió identificar las necesidades a satisfacer, las especialidades o materias a tomarse en cuenta entre otros aspectos importantes. Así inicia la etapa investigativa que permitió identificar si la malla curricular de la carrera de Ingeniería en Mantenimiento Automotriz se encuentra acorde o satisface las necesidades del sector automotriz del Norte del País. Se identifico que existen varias necesidades en el sector automotriz que no son satisfechas y que no constan como materias en la actual malla curricular, las cuales deberían ser incluidas, para obtener Ingenieros que al momento de su desempeño profesional puedan satisfacerlas. La necesidad de investigar si la malla curricular actual se encuentra acorde a las necesidades del sector, nace debido a que no existe investigación alguna sobre la actualización de las mallas curriculares anteriores, lo cual genera incertidumbre e inconformidad tanto en los futuros y actuales ingenieros como en los dueños de Empresas, Talleres, y Mecánicas que los contratan

Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol

[Background] In-stent thrombosis after mechanical thrombectomy (MT) worsen outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Although an optimal antiplatelet therapy is needed, the best approach to avoid in-stent thrombosis is yet to be elucidated.[Hypothesis] Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL.[Methods] The ATILA-trial is a multicenter, prospective, phase IV, randomized, controlled (aspirin group as control), assessor-blinded clinical trial. Patients fulfilling inclusion criteria (AIS due to TL, ASPECTS ⩾ 6, pre-stroke modified Rankin Scale ⩽2 and onset <24 h) will be randomized (1:1) at MT onset to experimental (intravenous tirofiban) or control group (intravenous aspirin). Intravenous aspirin will be administered at a 500 mg single dose and tirofiban at a 500 µg bolus followed by a 200 µg/h infusion during first 22 h. All patients will be followed up to 3 months. Sample size estimated is 240 patients.[Outcomes] The primary efficacy outcome is the proportion of patients with carotid in-stent thrombosis within the first 24 h after MT. The primary safety outcome is the rate of symptomatic intracranial hemorrhage. Secondary outcomes include functional independence defined as modified Rankin Scale 0–2, proportion of patients undergoing rescue therapy due to in-stent aggregation during MT and carotid reocclusion at 30 days.[Discussion] ATILA-trial will be the first clinical trial regarding the best antiplatelet therapy to avoid in-stent thrombosis after MT in patients with TL.[Trial registration] NCT0522596.This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The Spanish Clinical Research Network (SCReN-Code:21.033) also contributed to the study. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. M. Medina-Rodríguez was granted a Rio Hortega contract (CM21/00096). The project was included in the Cooperative Cerebrovascular Disease Research Network (INVICTUS) (RD16/0019/0015).Peer reviewe

El gran juego de la paz

El trabajo obtuvo el Tercer Premio de la Modalidad B de los 'Premios Tomás García Verdejo' a las buenas prácticas educativas en la Comunidad Autónoma de Extremadura para el curso académico 2013/2014Se presentan un conjunto de actividades que se han llevado a cabo en el IESO Matías Ramón Martínez de Burguillos del Cerro (Badajoz) desde el curso 2007-2008 para la conmemoración del Día de la no violencia y la paz y con el desarrollo de 'El gran juego de la paz'. Entre los objetivos que se perseguían estaban: promocionar valores de paz, igualdad y no violencia entre los alumnos, promover la educación para la salud, el fomento de la práctica deportiva y el respeto por el medio ambiente, adquirir una buena inteligencia emocional, despertar el gusto e interés por la lectura y la investigación en la comunidad educativa, promover el uso de las nuevas tecnologías, desarrollar el plurilingüísmo en el alumnado, potenciar la integración escolar, aprender a resolver conflictos escolares de manera pacífica y democrática, fomentar la participación e implicación de la familia, profesorado, asociaciones locales, ayuntamiento, etc. en la vida escolar del centro y crear un clima de convivencia idóneo entre todos los sectores de la comunidad escolarExtremaduraES

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.

A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was to characterize the resistance profile of a large cohort of patients failing DAA-based treatments, and investigate the relationship between HCV subtype and failure, as an aid to optimizing management of these patients. A new, standardized HCV-RAS testing protocol based on deep sequencing was designed and applied to 220 previously subtyped samples from patients failing DAA treatment, collected in 39 Spanish hospitals. The majority had received DAA-based interferon (IFN) α-free regimens; 79% had failed sofosbuvir-containing therapy. Genomic regions encoding the nonstructural protein (NS) 3, NS5A, and NS5B (DAA target regions) were analyzed using subtype-specific primers. Viral subtype distribution was as follows: genotype (G) 1, 62.7%; G3a, 21.4%; G4d, 12.3%; G2, 1.8%; and mixed infections 1.8%. Overall, 88.6% of patients carried at least 1 RAS, and 19% carried RAS at frequencies below 20% in the mutant spectrum. There were no differences in RAS selection between treatments with and without ribavirin. Regardless of the treatment received, each HCV subtype showed specific types of RAS. Of note, no RAS were detected in the target proteins of 18.6% of patients failing treatment, and 30.4% of patients had RAS in proteins that were not targets of the inhibitors they received. HCV patients failing DAA therapy showed a high diversity of RAS. Ribavirin use did not influence the type or number of RAS at failure. The subtype-specific pattern of RAS emergence underscores the importance of accurate HCV subtyping. The frequency of "extra-target" RAS suggests the need for RAS screening in all three DAA target regions